31.82
price down icon4.39%   -1.46
after-market After Hours: 31.82
loading
Agios Pharmaceuticals Inc stock is traded at $31.82, with a volume of 980.15K. It is down -4.39% in the last 24 hours and down -25.46% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
See More
Previous Close:
$33.28
Open:
$33.38
24h Volume:
980.15K
Relative Volume:
1.22
Market Cap:
$1.88B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.8011
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-11.36%
1M Performance:
-25.46%
6M Performance:
-33.78%
1Y Performance:
+45.03%
1-Day Range:
Value
$31.48
$33.82
1-Week Range:
Value
$31.48
$35.23
52-Week Range:
Value
$20.96
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Name
Agios Pharmaceuticals Inc
Name
Phone
617-649-8600
Name
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
386
Name
Twitter
@AgiosPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
31.82 1.88B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.96 107.75B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
693.23 76.83B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
659.81 39.72B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
249.16 32.48B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.76 27.01B 3.30B -501.07M 1.03B -2.1146

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-10-24 Resumed Raymond James Outperform
Sep-27-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-08-24 Initiated Cantor Fitzgerald Overweight
Feb-03-23 Initiated Piper Sandler Overweight
Nov-17-22 Upgrade Goldman Sell → Neutral
Jul-27-22 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-03-21 Initiated BofA Securities Buy
Jul-30-21 Downgrade Goldman Neutral → Sell
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-10-21 Initiated H.C. Wainwright Buy
Mar-01-21 Downgrade JP Morgan Overweight → Neutral
Mar-01-21 Upgrade SVB Leerink Mkt Perform → Outperform
Feb-26-21 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20 Upgrade Barclays Equal Weight → Overweight
Mar-04-20 Initiated Barclays Equal Weight
Nov-26-19 Initiated Cantor Fitzgerald Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
May-23-19 Resumed Goldman Neutral
Feb-15-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-25-18 Initiated Leerink Partners Mkt Perform
May-23-18 Initiated Citigroup Buy
Apr-11-18 Reiterated Credit Suisse Outperform
Feb-15-18 Reiterated Needham Buy
Feb-15-18 Reiterated SunTrust Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Aug-10-17 Reiterated Needham Buy
Aug-08-17 Reiterated SunTrust Buy
Aug-02-17 Upgrade Leerink Partners Mkt Perform → Outperform
Jun-26-17 Downgrade Janney Buy → Neutral
Jan-17-17 Upgrade Oppenheimer Perform → Outperform
Oct-24-16 Initiated Needham Buy
Jun-13-16 Upgrade JP Morgan Neutral → Overweight
May-18-16 Reiterated SunTrust Buy
View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

pulisher
Jan 15, 2025

Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR

Jan 15, 2025
pulisher
Jan 14, 2025

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 13, 2025

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan

Jan 13, 2025
pulisher
Jan 12, 2025

Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey

Jan 12, 2025
pulisher
Jan 12, 2025

The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter

Jan 12, 2025
pulisher
Jan 11, 2025

Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN

Jan 11, 2025
pulisher
Jan 11, 2025

Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail

Jan 11, 2025
pulisher
Jan 11, 2025

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN

Jan 11, 2025
pulisher
Jan 10, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat

Jan 10, 2025
pulisher
Jan 08, 2025

FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Quantisnow

Jan 08, 2025
pulisher
Jan 08, 2025

FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan

Jan 08, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada

Jan 07, 2025
pulisher
Jan 07, 2025

Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter

Jan 07, 2025
pulisher
Jan 07, 2025

FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia

Jan 07, 2025
pulisher
Jan 06, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 06, 2025

FDA approves label update for Agios's PYRUKYND - Investing.com India

Jan 06, 2025
pulisher
Jan 05, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat

Jan 05, 2025
pulisher
Jan 04, 2025

JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Jan 04, 2025
pulisher
Jan 03, 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times

Jan 03, 2025
pulisher
Dec 30, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat

Dec 30, 2024
pulisher
Dec 29, 2024

Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN

Dec 29, 2024
pulisher
Dec 28, 2024

Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Dec 28, 2024
pulisher
Dec 23, 2024

Objective long/short (AGIO) Report - Stock Traders Daily

Dec 23, 2024
pulisher
Dec 19, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9%Should You Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 18, 2024

Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK

Dec 18, 2024
pulisher
Dec 18, 2024

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times

Dec 18, 2024
pulisher
Dec 18, 2024

Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan

Dec 18, 2024
pulisher
Dec 17, 2024

Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily

Dec 17, 2024
pulisher
Dec 16, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga

Dec 16, 2024
pulisher
Dec 16, 2024

State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Zacks Research Issues Negative Forecast for AGIO Earnings - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Fmr LLC Increases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Agios Pharmaceuticals director David Scadden sells $9,256 in stock By Investing.com - Investing.com Australia

Dec 14, 2024
pulisher
Dec 13, 2024

Agios Pharmaceuticals director David Scadden sells $9,256 in stock - Investing.com

Dec 13, 2024

Agios Pharmaceuticals Inc Stock (AGIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Milanova Tsveta
Chief Commercial Officer
Jan 06 '25
Sale
32.18
2,804
90,233
18,906
$18.19
price down icon 0.05%
$30.95
price up icon 0.68%
$72.47
price up icon 0.01%
$366.39
price up icon 1.31%
biotechnology ONC
$205.34
price up icon 1.79%
$112.76
price down icon 0.80%
Cap:     |  Volume (24h):